Charles Schwab Investment Management Inc. Purchases 28,256 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Charles Schwab Investment Management Inc. boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYFree Report) by 9.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,167 shares of the company’s stock after purchasing an additional 28,256 shares during the period. Charles Schwab Investment Management Inc. owned about 0.54% of Harmony Biosciences worth $10,309,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its holdings in Harmony Biosciences by 534,795.2% during the 4th quarter. Pacer Advisors Inc. now owns 1,224,910 shares of the company’s stock worth $39,565,000 after purchasing an additional 1,224,681 shares in the last quarter. Federated Hermes Inc. raised its position in Harmony Biosciences by 2,132.8% in the 4th quarter. Federated Hermes Inc. now owns 525,337 shares of the company’s stock valued at $16,968,000 after buying an additional 501,809 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Harmony Biosciences by 18.3% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,420,000 shares of the company’s stock valued at $46,533,000 after acquiring an additional 220,000 shares in the last quarter. HealthInvest Partners AB purchased a new position in Harmony Biosciences during the 4th quarter worth $4,684,000. Finally, Vanguard Group Inc. grew its stake in shares of Harmony Biosciences by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,684,152 shares of the company’s stock worth $120,730,000 after acquiring an additional 88,295 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Down 1.6 %

HRMY stock opened at $28.87 on Friday. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $39.26. The stock has a fifty day moving average of $30.50 and a 200-day moving average of $31.10. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 12.50, a PEG ratio of 0.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.07 and a current ratio of 3.11.

Harmony Biosciences (NASDAQ:HRMYGet Free Report) last posted its earnings results on Tuesday, April 30th. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.07. The firm had revenue of $154.62 million during the quarter, compared to the consensus estimate of $154.10 million. Harmony Biosciences had a net margin of 22.30% and a return on equity of 28.26%. The company’s revenue was up 29.8% on a year-over-year basis. During the same quarter last year, the company earned $0.48 earnings per share. As a group, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.53 earnings per share for the current year.

Analyst Ratings Changes

HRMY has been the topic of several analyst reports. Mizuho cut their price target on shares of Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research report on Friday, April 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 30th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.63.

Get Our Latest Report on HRMY

Insider Buying and Selling at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 11,979 shares of the business’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $32.00, for a total transaction of $383,328.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Company Profile

(Free Report)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

See Also

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.